References
- WHO. Global incidence and prevalence of selected curable sexually transmitted infections - 2008. WHO, Geneva, Switzerland; 2012
- WHO. Department of Reproductive Health and Research. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. WHO, Geneva, Switzerland; 2012. p. 1-36
- Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009;7:821-34
- Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012;7:1401-22
- Unemo M, Shafer WM. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann NY Acad Sci 2011;1230:E19-28
- Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013;309:163-70
- Lewis DA, Sriruttan C, Müller EE, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum cephalosporin resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrobial Chemother 2013;68:1267-70
- Ndowa F, Lusti-Narasimhan M, Unemo M. The serious threat of multidrug-resistant and untreatable gonorrhoea: the pressing need for global action to control the spread of antimicrobial resistance, and mitigate the impact on sexual and reproductive health. Sex Transm Infect 2012;88:317-18
- CDC. Cephalosporin-resistant Neisseria gonorrhoeae public health response plan. 2012. p. 1-43
- European CDC. Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe. ECDC; Stockholm, Sweden; 2012. p. 1-23
- Unemo M, Ison CA, Cole M, et al. Gonorrhoea and gonococcal antimicrobial resistance surveillance networks in the WHO European Region, including the independent countries of the former Soviet Union. Sex Transm Infect 2013;89(Suppl 4):iv42-6
- Ndowa FJ, Francis JM, Machiha A, et al. Gonococcal antimicrobial resistance: perspectives from the African region. Sex Transm Infect 2013;89(Suppl 4):iv11-15
- Low N, Unemo M, Jensen JS, et al. Molecular diagnostics for gonorrhoea: implications for antimicrobial resistance and the threat of untreatable gonorrhoea. PLoS Med 2014;11(2):e1001598
- Goire N, Lahra MM, Chen M, et al. Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance. Nat Rev Microbiol 2014;12(3):223-9
- Grad YH, Kirkcaldy RD, Trees D, et al. Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study. Lancet Infect Dis 2014;14(3):220-6
- Ohnishi M, Unemo M. Phylogenomics for drug-resistant Neisseria gonorrhoeae. Lancet Infect Dis 2014;14(3):179-80
- CDC. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012;61:590-4
- Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013;24:85-92
- Ison CA, Deal C, Unemo M. Current and future treatment options for gonorrhoea. Sex Transm Infect 2013;89(Suppl 4):iv52-6
- Ison CA, Town K, Obi C, et al. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011. Lancet Infect Dis 2013;13:762-8
- Hook EW, Van Der Pol B. Evolving gonococcal antimicrobial resistance: research priorities and implications for management. Sex Transm Infect 2013;89(Suppl 4):iv60-2